EP3033101
Aðferðir til að minnka elnunarhraða astma með því að nota benralísúmab
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
7.8.2014EP published:
19.12.2018EP application number:
14835826.0
EP translation filed:
4.3.2019Grant published:
15.3.2019EPO information:
European Patent Register
Max expiry date:
6.8.2034Expiry date:
6.8.2026Next due date:
31.8.2026
Title:
METHODS FOR REDUCING EXACERBATION RATES OF ASTHMA USING BENRALIZUMAB
Timeline
Today
7.8.2014EP application
19.12.2018EP Publication
4.3.2019Translation submitted
15.3.2019Registration published
6.8.2026Expires
Owner
Name:
AstraZeneca ABAddress:
151 85 Södertälje, SE
Inventor
Name:
WARD, ChristineAddress:
Gaithersburg, MD, US
Name:
ROSKOS, LorinAddress:
Gaithersburg, MD, US
Name:
WANG, BingAddress:
Gaithersburg, MD, US
Name:
RAIBLE, DonaldAddress:
Berwyn, PA, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
201361864944 PDate:
12.8.2013Country:
US
Classification
Categories:
A61K 39/00, A61K 39/395, G01N 33/48, C07K 16/24
Annual fees
Number
Paid
Expires
Payer
Number: 6
Paid: 19.8.2019
Expires: 6.8.2020
Payer: Árnason Faktor
Number: 7
Paid: 8.7.2020
Expires: 6.8.2021
Payer: Árnason Faktor ehf.
Number: 8
Paid: 12.7.2021
Expires: 6.8.2022
Payer: Árnason Faktor ehf.
Number: 9
Paid: 5.7.2022
Expires: 6.8.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 11.7.2023
Expires: 6.8.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 9.7.2024
Expires: 6.8.2025
Payer: Árnason Faktor ehf.
Number: 12
Paid: 5.8.2025
Expires: 6.8.2026
Payer: Árnason Faktor ehf.